A Multi-Parametric Imaging Investigation of the Response of C6 Glioma Xenografts to MLN0518 (Tandutinib) Treatment

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Boult, Jessica K R ^a   Terkelsen, Jennifer ^b   Walker Samuel, Simon ^a,c   Bradley, Daniel P ^b   Robinson, Simon P ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b MILLENNIUM PHARMACEUTICALS INC   (United States)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; BIOLOGICAL MARKER; CARBOGEN; MLN 0518; TANDUTINIB; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; BLOOD FLOW; BLOOD VESSEL DIAMETER; BLOOD VOLUME; CONTROLLED STUDY; DIFFUSION WEIGHTED IMAGING; DRUG RESISTANCE; DRUG RESPONSE; DYNAMIC CONTRAST ENHANCED MAGNETIC RESONANCE IMAGING; FEMALE; GLIOMA; HEMODYNAMICS; HISTOPATHOLOGY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; QUANTITATIVE ANALYSIS; RADIOSENSITIVITY; RAT; SIGNAL TRANSDUCTION; SUSCEPTIBILITY WEIGHTED IMAGING; TUMOR GROWTH; TUMOR NECROSIS; TUMOR XENOGRAFT;

ANIMALS; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CONTRAST MEDIA; DIAGNOSTIC IMAGING; DIFFUSION MAGNETIC RESONANCE IMAGING; FEMALE; GLIOMA; HUMANS; MICE; MICE, NUDE; PIPERAZINES; QUINAZOLINES; RATS; TUMOR MARKERS, BIOLOGICAL; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS;

EID: 84876880478     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0063024     Document Type: Article

References (43)

1. Folkman J, (1985) Tumor angiogenesis. Adv Cancer Res 43: 175-203.
2. Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, et al. (2000) Vascular-specific growth factors and blood vessel formation. Nature 407: 242-248.
3. Yuan F, Salehi HA, Boucher Y, Vasthare US, Tuma RF, et al. (1994) Vascular permeability and microcirculation of gliomas and mammary carcinomas transplanted in rat and mouse cranial windows. Cancer Res 54: 4564-4568.
4. Heldin CH, Westermark B, (1999) Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev 79: 1283-1316.
5. Oikawa T, Onozawa C, Sakaguchi M, Morita I, Murota S, (1994) Three isoforms of platelet-derived growth factors all have the capability to induce angiogenesis in vivo. Biol Pharm Bull 17: 1686-1688.
6. Guo P, Hu B, Gu W, Xu L, Wang D, et al. (2003) Platelet-derived growth factor-B enhances glioma angiogenesis by stimulating vascular endothelial growth factor expression in tumor endothelia and by promoting pericyte recruitment. Am J Pathol 162: 1083-1093.
7. Hellström M, Gerhardt H, Kalén M, Li X, Eriksson U, et al. (2001) Lack of pericytes leads to endothelial hyperplasia and abnormal vascular morphogenesis. J Cell Biol 153: 543-553.
8. Lindahl P, Johansson BR, Levéen P, Betsholtz C, (1997) Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science 277: 242-245.
9. Heldin CH, Rubin K, Pietras K, Ostman A, (2004) High interstitial fluid pressure - an obstacle in cancer therapy. Nat Rev Cancer 4: 806-813.
10. Kelly LM, Yu JC, Boulton CL, Apatira M, Li J, et al. (2002) CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML). Cancer Cell 1: 421-432.
11. Waterton JC, Pylkkanen L, (2012) Qualification of imaging biomarkers for oncology drug development. Eur J Cancer 48: 409-415.
12. Leach M, Brindle K, Evelhoch J, Griffiths J, Horsman M, et al. (2005) The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations. Br J Cancer 92: 1599-1610.
13. Robinson SP, Howe FA, Griffiths JR, Ryan AJ, Waterton JC, (2007) Susceptibility contrast magnetic resonance imaging determination of fractional tumor blood volume: a noninvasive imaging biomarker of response to the vascular disrupting agent ZD6126. Int J Radiat Oncol Biol Phys 69: 872-879.
14. Robinson SP, Rijken PF, Howe FA, McSheehy PM, van der Sanden BP, et al. (2003) Tumor vascular architecture and function evaluated by non-invasive susceptibility MRI methods and immunohistochemistry. J Magn Reson Imaging 17: 445-454.
15. Workman P, Aboagye E, Balkwill F, Balmain A, Bruder G, et al. (2010) Guidelines for the welfare and use of animals in cancer research. Br J Cancer 102: 1555-1577.
16. Walker-Samuel S, Boult JK, McPhail LD, Box G, Eccles SA, et al. (2012) Non-invasive in vivo imaging of vessel calibre in orthotopic prostate tumour xenografts. Int J Cancer 130: 1284-1293.
17. Bradley DP, Tessier JJ, Lacey T, Scott M, Jurgensmeier JM, et al. (2009) Examining the acute effects of cediranib (RECENTIN, AZD2171) treatment in tumor models: a dynamic contrast-enhanced MRI study using gadopentate. Magn Reson Imaging 27: 377-384.
18. Walker-Samuel S, Orton M, McPhail LD, Boult JK, Box G, et al. (2010) Bayesian estimation of changes in transverse relaxation rates. Magn Reson Med 64: 914-921.
19. Troprès I, Lamalle L, Péoc'h M, Farion R, Usson Y, et al. (2004) In vivo assessment of tumoral angiogenesis. Magn Reson Med 51: 533-541.
20. Yablonskiy DA, Haacke EM, (1994) Theory of NMR signal behavior in magnetically inhomogeneous tissues: the static dephasing regime. Magn Reson Med 32: 749-763.
21. Boult JK, Walker-Samuel S, Jamin Y, Leiper JM, Whitley GS, et al. (2011) Active site mutant dimethylarginine dimethylaminohydrolase 1 expression confers an intermediate tumour phenotype in C6 gliomas. J Pathol 225: 344-352.
22. Robinson SP, Ludwig C, Paulsson J, Ostman A, (2008) The effects of tumor-derived platelet-derived growth factor on vascular morphology and function in vivo revealed by susceptibility MRI. Int J Cancer 122: 1548-1556.
23. Yu XF, Yang C, Liang LH, Liu B, Zhou B, et al. (2006) Inhibition of human leukemia xenograft in nude mice by adenovirus-mediated tissue inhibitor of metalloproteinase-3. Leukemia 20: 1-8.
24. Howe FA, McPhail LD, Griffiths JR, McIntyre DJ, Robinson SP, (2008) Vessel size index magnetic resonance imaging to monitor the effect of antivascular treatment in a rodent tumor model. Int J Radiat Oncol Biol Phys 71: 1470-1476.
25. Wilkinson S, O'Prey J, Fricker M, Ryan KM, (2009) Hypoxia-selective macroautophagy and cell survival signaled by autocrine PDGFR activity. Genes Dev 23: 1283-1288.
26. Tuettenberg J, Friedel C, Vajkoczy P, (2006) Angiogenesis in malignant glioma - a target for antitumor therapy? Crit Rev Oncol Hematol 59: 181-193.
27. Calzolari F, Malatesta P, (2010) Recent insights into PDGF-induced gliomagenesis. Brain Pathol 20: 527-538.
28. Barrios CH, Viola FS, Coutinho LM, Paglioli E, (2006) Determination of expression of platelet derived growth factor receptors (PDGFR) in astrocytic tumors. J Clin Oncol 24: 11518.
29. Hermansson M, Nistér M, Betsholtz C, Heldin CH, Westermark B, et al. (1988) Endothelial cell hyperplasia in human glioblastoma: coexpression of mRNA for platelet-derived growth factor (PDGF) B chain and PDGF receptor suggests autocrine growth stimulation. Proc Natl Acad Sci U S A 85: 7748-7752.
30. Hermanson M, Funa K, Hartman M, Claesson-Welsh L, Heldin CH, et al. (1992) Platelet-derived growth factor and its receptors in human glioma tissue: expression of messenger RNA and protein suggests the presence of autocrine and paracrine loops. Cancer Res 52: 3213-3219.
31. Abramsson A, Lindblom P, Betsholtz C, (2003) Endothelial and nonendothelial sources of PDGF-B regulate pericyte recruitment and influence vascular pattern formation in tumors. J Clin Invest 112: 1142-1151.
32. Morikawa S, Baluk P, Kaidoh T, Haskell A, Jain RK, et al. (2002) Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. Am J Pathol 160: 985-1000.
33. Benjamin LE, Hemo I, Keshet E, (1998) A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF. Development 125: 1591-1598.
34. Walker-Samuel S, Orton M, McPhail L, Robinson S, (2009) Robust estimation of the apparent diffusion coefficient (ADC) in heterogeneous solid tumors. Magn Reson Med 62: 420-429.
35. Harris AL, (2002) Hypoxia - a key regulatory factor in tumour growth. Nat Rev Cancer 2: 38-47.
36. Höckel M, Vaupel P, (2001) Biological consequences of tumor hypoxia. Semin Oncol 28: 36-41.
37. Wysocki PJ, Zolnierek J, Szczylik C, Mackiewicz A, (2008) Targeted therapy of renal cell cancer. Curr Opin Investig Drugs 9: 570-575.
38. Köhne CH, Lenz HJ, (2009) Chemotherapy with targeted agents for the treatment of metastatic colorectal cancer. Oncologist 14: 478-488.
39. Pàez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, et al. (2009) Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15: 220-231.
40. Song S, Ewald AJ, Stallcup W, Werb Z, Bergers G, (2005) PDGFRbeta+ perivascular progenitor cells in tumours regulate pericyte differentiation and vascular survival. Nat Cell Biol 7: 870-879.
41. Bergers G, Hanahan D, (2008) Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 8: 592-603.
42. O'Connor JP, Jackson A, Parker GJ, Jayson GC, (2007) DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents. Br J Cancer 96: 189-195.
43. Boult JK, Jamin Y, Jacobs V, Gilmour LD, Walker-Samuel S, et al. (2012) False-negative MRI biomarkers of tumour response to targeted cancer therapeutics. Br J Cancer 106: 1960-1966.